EARLY ONLINE RELEASE
|
|
- Walter Berry
- 5 years ago
- Views:
Transcription
1 EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: /arpa OA The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available College of American Pathologists
2 Original Article Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer Liyun Cao, PhD; Chi Hyun Lee, PhD; Jing Ning, PhD; Beverly C. Handy, MD; Elizabeth A. Wagar, MD; Qing H. Meng, MD, PhD Context. Prostate cancer antigen 3 (PCA3) is a noncoding RNA that is highly overexpressed in prostate cancer (PCa) tissue and excreted in urine in patients with PCa. Objective. To assess the clinical utility of urinary PCA3 in men at risk of PCa. Design. We retrospectively reviewed a cohort of 271 men (median age, 63 years) with elevated prostate-specific antigen (PSA), and/or strong family history, and/or abnormal digital rectal examination findings. Diagnostic sensitivity, specificity, positive and negative predictive values (PPV, NPV), positive and negative likelihood ratios (LRþ, LR ), and diagnostic odds ratio (DOR), and area under the receiver-operating characteristic curves (AUC) were evaluated. Results. PCA3 score was a significant predictor of prostate biopsy outcome (P,.001). A PCA3 score of 30 was the optimal cutoff for our study cohort, with a diagnostic sensitivity of 72.7%, specificity of 67.5%, PPV of 47.1%, NPV of 86.2%, LRþ of 2.24, LR of 0.40, and DOR of At this cutoff score, the PCA3 assay could avoid 57.4% of unnecessary invasive biopsies in the overall study cohort and 70.3% in the subgroup with PSA level in the gray zone (4 10 ng/ml). A logistic regression algorithm combining PCA3 with PSA increased the AUC from for PSA-only to (P,.001). The logistic combined marker gained the ability to discriminate low-grade from high-grade cancers. Conclusions. Our data suggest that PCA3 improves the diagnostic sensitivity and specificity of PSA and that the combination of PCA3 with PSA gives better overall performance in identification of PCa than serum PSA alone in the high-risk population. (Arch Pathol Lab Med. doi: /arpa OA) Prostate cancer (PCa) is the most frequently diagnosed Thus, false-positive PSA results lead to unnecessary biopsy, cancer in US men, with an estimated new cases an invasive procedure whose associated risks include expected in This high incidence is largely due to the bleeding and sepsis. 8,9 False-negative results also occur; widespread use of prostate-specific antigen (PSA) as a 20% to 25% of patients with PCa have a PSA level less than screening and diagnostic test for PCa. 2 PSA is an androgenregulated 4.0 ng/ml. 10 Therefore, more specific and sensitive bio- serine protease encoded by the KLK3 gene. It is markers are needed for more accurate diagnosis of PCa. secreted exclusively by prostate epithelial cells, and the Another disadvantage of PSA is its inability to discriminate low-grade, low-stage indolent tumors from more serum concentration is very low in men with a healthy prostate. 3 Since normal prostate epithelium can produce aggressive disease. Treatment of indolent cancer may PSA too, serum PSA level may be elevated not only in PCa negatively affect patients life qualities by causing psychological distress, side effects, or complications. 11,12 As most but also in noncancerous conditions such as prostatic cases of newly diagnosed PCa (92%) are local or regional inflammation, benign prostate hyperplasia, and urinary tract disease, infection. 4 The current recommendation is that a PSA level biomarkers that can distinguish aggressive from less aggressive disease are needed to reduce overdiagnosis of 4.0 ng/ml or greater is a basis for referral for further and overtreatment of indolent PCa. evaluation or biopsy. 5 However, the positive biopsy rates are Among the numerous novel biomarkers identified in an about 25% in men with a PSA level in the gray zone (4 10 effort to overcome these weaknesses of PSA, prostate cancer ng/ml) and 50% in men with PSA greater than 10 ng/ml. 6,7 antigen 3 (PCA3) is one of the most promising. Identified in 1999, PCA3 is a long noncoding RNA located on 9q PCA3 is PCa specific with overexpression in PCa but not in Accepted for publication October 4, From the Departments of Laboratory Medicine (Drs Cao, Handy, benign prostate tissue 13,14 or other types of normal tissue or Wagar, and Meng) and Biostatistics (Drs Lee and Ning), The University of Texas MD Anderson Cancer Center, Houston, Texas. tumors. 15 It is excreted in the urine of patients with PCa. In 2012, the Progensa urinary PCA3 assay (Hologic, Marlborough, Massachusetts) was approved by the US Food and The authors have no relevant financial interest in the products or companies described in this article. Drug Administration (FDA) as an aid in decision making for Corresponding author: Qing H. Meng, MD, PhD, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer repeated biopsy in men older than 50 years who have had 1 Center, 1515 Holcombe Blvd, Unit 37, Houston, TX or more previous negative prostate biopsy results and for ( qhmeng@mdanderson.org). whom a repeated biopsy would be recommended by a Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al 1
3 urologist. Many studies have been performed hitherto to test the clinical utility of PCA3. Most of them showed that this noninvasive assay is useful in predicting prostate biopsy outcome However, there are some controversies over the optimal PCA3 cutoff score to detect PCa and the ability of PCA3 to predict tumor aggressiveness. The aims of this study were to evaluate the clinical performance of the urinary PCA3 assay in a clinical setting with men at high risk of PCa, to assess the correlation between PCA3 score and tumor aggressiveness, to achieve an optimal PCA3 cutoff score for PCa detection, and to provide a logistic regression model for better detection of PCa by combining urinary PCA3 score with serum PSA level and other demographic and clinical variables such as age, race, family history, digital rectal examination (DRE) findings, and prostate volume. METHODS Study Cohort We retrospectively reviewed 302 PCA3 and PSA results from 287 men (median age, 63 years; range, years) obtained during the period from January 2013 to March 2016 at The University of Texas MD Anderson Cancer Center (Houston, Texas). The institutional review board approval for this study was waived by our institute. This investigation was performed by following the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines. 19 These men represent a population at high risk of PCa, with elevated PSA level (.4 ng/ml) or increasing PSA dynamics, and/or strong family history of PCa, and/or abnormal findings on DRE, with or without a previous negative biopsy finding. For the 16 men who had more than 1 PSA or PCA3 result, the man s first result during the study period was used and the repeated results were excluded. Of the 287 men selected, 15 (5.2%) were excluded because no biopsy was performed to confirm the diagnosis. The final study cohort included 271 men, of which 72 (27%) underwent initial biopsy (patients have never done biopsy before) and 199 (73%) underwent repeated biopsy (patients previously had 1 or more negative biopsy findings in a time range of 1 10 years). Data Collection Clinical and demographic data were obtained from the medical records. Urine specimens for PCA3 measurement were collected after DRE. PCA3 was assayed with the Progensa PCA3 kit (Hologic). PCA3 scores were reported as a ratio of urinary PCA3 mrna to PSA mrna multiplied by Serum specimens were collected before prostate examination and PSA was tested on a Tosoh automated AIA-2000 enzyme immunoassay analyzer (Tosoh Bioscience, South San Francisco, California). The PCA3 and PSA assays were tested concurrently or within 2 weeks. Diagnosis of PCa was confirmed by biopsy using 12 or more cores, which was performed within 1 to 6 months before or after the PCA3 and PSA tests. Prostate volume was determined by magnetic resonance imaging using the ellipsoid formula: V ¼ H 3 W 3 L 3 p/6, where H is height, W is width, and L is length of the prostate in the 3-D image. Statistical Analyses The men s clinical characteristics were summarized by using descriptive statistics. Two-sample tests were conducted to determine whether the PCA3 score and PSA level were significantly different between men found to have PCa and those not found to have PCa. The area under the receiver-operating characteristic (ROC) curves (AUC) was quantified to evaluate the diagnostic performance of PCA3 score, PSA level, and the two combined. The performance characteristics of both PCA3 and PSA were evaluated by determining the diagnostic sensitivity and, specificity, positive and negative predictive values (PPV, NPV), positive and negative likelihood ratios (LRþ, LR ), and diagnostic odds ratio (DOR) with 95% CIs. Multivariable logistic regression analyses were conducted to develop a model incorporating the 2 biomarkers and other risk factors such as age, race, family history, DRE findings, and prostate volume. Statistical analyses were performed by using R software (version 3.2.3, R Foundation for Statistical Computing, Vienna, Austria) and Medcalc (MedCalc Software, Ostend, Belgium). RESULTS Clinical Characteristics of the Study Cohort The study cohort selection and biopsy results are summarized in Figure 1. Biopsy results revealed newly diagnosed prostate adenocarcinoma in 77 of the 271 men (28.4%). Of the 72 men undergoing initial biopsy, 9 (12.5%) had a positive biopsy result. Of the 199 men undergoing a repeaed biopsy, 68 (34.2%) had a positive biopsy result, a significantly higher positivity rate than initial biopsy (P,.001). Since the sample size for positive initial biopsy result was not large enough for further analysis, all initial and repeated biopsy results were treated equally as a mixed biopsy data set. The baseline demographic and clinical characteristics of the 271 men who underwent biopsy are summarized in Table 1 and are stratified by biopsy result (PCa versus no PCa). Differences in risk factors such as age, race, family history, and abnormal DRE findings did not reach statistical significance between the PCa group (n ¼ 77) and the no PCa group (n ¼ 194; all P..05). Prostate volume, repeated biopsy, and PCA3 score were identified as significant univariable predictors of prostate biopsy outcome (all P.001). However, serum PSA level did not show significant association with biopsy outcome (P ¼.07). Clinical Performance Evaluation of Urinary PCA3 Assay Compared with men without PCa, those with PCa showed a significantly higher median PCA3 score (P,.001) but not a significantly higher PSA level (P ¼.07). Further analysis of the correlation between PCA3 score and biopsy result showed that the probability of a positive biopsy outcome increased as the PCA3 score increased, while positive biopsy results were associated with the entire range of PSA levels (Figure 2, A and B). Correlation analysis showed no significant correlation between PCA3 score and PSA level (Spearman rank correlation: r ¼ 0.05; P ¼.44) or between PCA3 score and prostate volume (r ¼ 0.03; P ¼.65). Men with a greater prostate volume (.30 ml) did not show a higher median PCA3 score than those with a smaller prostate volume (,30 ml; P ¼.41). Unlike serum PSA level, which differed significantly between the inflammation and noninflammation groups (P,.001), PCA3 score did not differ significantly between the 2 groups (P ¼.60) (Figure 3, A and B). To determine whether PCA3 score can predict tumor aggressiveness in terms of Gleason score, PCA3 scores from the men with a positive biopsy result (n ¼ 77) were analyzed. No significant difference in PCA3 score was detected between the men with a low-grade tumor (Gleason score ¼ 6, contemporary grading group 1, n ¼ 25) and those with a high-grade tumor (Gleason score 7; contemporary grading group 2, 3, 4, and 5; n ¼ 52; P ¼.12). Similar results were observed for PSA level (P ¼.13) (Table 2). To assess the test accuracy of the PCA3 assay, AUC was quantified by using R software. The AUC for PCA3 was 0.72 (95% CI, ), significantly greater than that for PSA, which was 0.57 (95% CI, ; P ¼.007; Figure 4, A). To 2 Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al
4 Figure 1. Study cohort selection and biopsy results. Abbreviations: HGPIN, high-grade prostatic intraepithelial neoplasia; PCa, prostate cancer. test the clinical utility of PCA3 in men with a PSA level in the gray zone (n ¼ 174), the ROC curve was analyzed. The results showed that PCA3 had a greater AUC (0.70; 95% CI, ) than PSA (0.53; 95% CI, ; P ¼.004) in these men (Figure 4, B). To characterize the diagnostic performance of PCA3, the sensitivity, specificity, PPV, NPV, LRþ, LR, and DOR were calculated at different PCA3 score cutoffs of 25, 30, and 35 (Table 3). The cutoff score of 25 was used for FDA approval, 30 was chosen by our ROC analysis, and 35 has been reported by other studies. 18,20 To determine the optimal cutoff score, 2 different methods were used. 21 The first was to calculate the square of the distance on the ROC curve [d 2 ¼ (1 sensitivity) 2 þ (1 specificity) 2 ], where the smaller value was the better choice for cutoff. The second method was to calculate the Youden index [Youden index ¼ (sensitivity þ specificity) 1], where the larger value was the better choice for cutoff. The results showed that the cutoff of 30 had the smallest d 2 and largest Youden index (Table 3). Furthermore, considering that the aim of the PCA3 test is to reduce unnecessary invasive biopsies and overcome the overdiagnosis and overtreatment that results Table 1. Demographic and Clinical Characteristics of Study Population Variable a Overall (n ¼ 271) PCa (n ¼ 77) No PCa (n ¼ 194) P Value AUC,95% CI. Age, y 63 (59 68) 65 (59 69) 63 (59 68) , African American b 39 (14.4) 13 (17.1) 26 (13.4) , Positive family history c 50 (18.7) 16 (20.8) 34 (17.8) , Abnormal DRE result d 47 (18.4) 15 (21.1) 32 (17.4) , Volume, ml e 47.9 ( ) 36.1 ( ) 53.4 ( ) , Repeated biopsy f 198 (74.2) 67 (88.2) 131 (68.6) , PCA3 score 26.0 ( ) 42.0 ( ) 19.0 ( ), , a N (%) or median (interquartile range). All P values are results of PCa versus no PCa comparison using Fisher exact tests for count values and Kruskal-Wallis tests for median. Abbreviations: AUC, area under the curve; DRE, digital rectal examination; PCa, prostate cancer; PCA3, prostate cancer antigen 3. b African American versus non African American. One missing value. c Three missing values. d Sixteen missing values. e Ninety missing values. f Four missing values. Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al 3
5 Figure 2. Percentage of biopsy results positive for prostate cancer at various ranges of prostate cancer antigen 3 (PCA3) (A) and prostate-specific antigen (PSA) (B). Values in parentheses indicate sample size. Figure 3. Relationship of prostate cancer antigen 3 (PCA3) (A) and prostate-specific antigen (PSA) (B) with prostatic inflammation. Figure 4. Receiver-operating characteristic curves for prostate cancer antigen 3 (PCA3) and prostate-specific antigen (PSA) in (A) the whole study cohort and (B) the subgroup with PSA level in the gray zone (4 10 ng/ml). from the low specificity of PSA, a cutoff with higher specificity was needed. Among all 3 cutoffs compared, the cutoff of 30 gave the best performance in our study cohort, with a diagnostic sensitivity of 72.7%, specificity of 67.5%, PPV of 47.1%, NPV of 86.2%, LRþ of 2.24, LR of 0.40, and DOR of PCA3 score outperformed PSA level at a cutoff of 4.0 ng/ml, with a diagnostic sensitivity of 84.4%, specificity of 23.7%, PPV of 30.5%, NPV of 79.3%, LRþ of 1.11, LR of 0.66, and DOR of To further evaluate the clinical utility of PCA3 score in preventing unnecessary biopsy, the following formula was used to calculate the probability of avoided biopsy (PAB): (number of false-positive PSA results number of falsepositive PCA3 results)/number of false-positive PSA results. 22 The results showed that the PABs were 45.9%, 57.4%, and 62.8% at the cutoffs of 25, 30, and 35, respectively. In men with a PSA level in the gray zone, 4 Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al
6 Variable Table 2. Relationship With Tumor Aggressiveness (Biopsy Gleason Score) AUC (95% CI) Median at Gleason Score ¼ 6 Median at Gleason Score 7 P Value (Mann-Whitney Test) PSA, ng/ml 0.57 ( ) 6.1 (n ¼ 25) 7.1 (n ¼ 52).13 PCA3 score 0.72 ( ) 37.0 (n ¼ 25) 43.0 (n ¼ 52).12 PSA þ PCA ( ) 0.09 (n ¼ 25) 0.18 (n ¼ 52).04 PSA þ PCA3 þ prostate volume þ repeated biopsy 0.79 ( ) 0.12 (n ¼ 16) 0.21 (n ¼ 42).14 Abbreviations: AUC, area under the receiver-operating characteristic curve; PCA3, prostate cancer antigen 3; PSA, prostate-specific antigen. the PABs were 60.2%, 70.3%, and 70.3% at the cutoffs of 25, 30, and 35, respectively (Figure 5). Logistic Regression Model To improve the diagnostic accuracy of the PCA3 score, we performed a logistic regression analysis combining PCA3, PSA, and other PCa risk factors. By fitting a logistic regression model to the data, a PCA3-PSA combined marker was generated by computing þ PCA3 þ PSA. The AUC for the combined biomarker was 0.73 (95% CI, ), slightly higher than that for PCA3- only and significantly higher than that for PSA-only (P,.001; Figure 6, A). The combined biomarker was significantly associated with biopsy outcome (PCa versus no PCa, P,.001). Moreover, the combined biomarker had a significantly higher median value in men with a Gleason score of 7 or greater (median, 0.18) than in men with a Gleason score of 6 (median, 0.09; P ¼.04). After fitting univariable logistic regression models for each covariate, prostate volume and repeated biopsy were identified as significant risk factors (P,.001 and P,.01, respectively). Volume and repeated biopsy were incorporated into the PCA3-PSA combined biomarker, and a new biomarker was generated by computing ( þ PCA3 þ PSA Volume þ Repeated Biopsy). In this analysis, 91 men with missing volume or repeated biopsy data were excluded. Addition of the 2 significant risk factors increased the AUC of the PCA3-PSA combined biomarker to 0.79 (95% CI, ), significantly higher than the 0.68 (95% CI, ) for PSA-only (P ¼.016; Figure 6, B). The multivariable marker demonstrated a significant association with biopsy outcome (PCa versus no PCa, P,.001). However, it did not show a significant association with tumor aggressiveness (P ¼.14), partially because of the missing data. DISCUSSION While the urinary PCA3 assay was approved in 2012 by the FDA to aid in decision making for repeated prostate biopsy, its clinical utility has not been fully elucidated. In the present study, we retrospectively investigated the clinical performance of urinary PCA3 assay in the population undergoing initial or repeated biopsy and at high risk of PCa with elevated PSA, and/or strong family history, and/or abnormal DRE findings. In the univariable analysis, the classic risk factors such as age, race, family history, and abnormal DRE findings were not significantly associated with prostate biopsy outcome. In accordance with previous studies, 16,23 25 PCA3 score was significantly associated with biopsy outcome, and the urinary PCA3 assay outperformed the serum PSA test, with a significantly greater AUC. Furthermore, our findings are consistent with those of other studies showing that PCA3 score is independent of prostate volume and PSA level. 24,26,27 We also looked at the relationship between prostatic inflammation and PCA3 score, which has not been evaluated in many published studies. Vlaeminck- Guillem et al, 28 in a small study of 38 men (mean age, 37.5 years), found PCA3 score to be independent of chronic prostatitis. In our study, PCA3 score was not affected by prostatic inflammation, either acute or chronic. Finally, in our ROC analysis, PCA3 had a greater AUC than PSA in the subgroup whose PSA level was in the gray zone. These data suggest that PCA3 is a useful, independent diagnostic tool for PCa, especially in men with elevated PSA due to an enlarged prostate or prostatic inflammation. Since the optimal cutoff PCA3 score is still inconclusive, we compared the diagnostic performance characteristics of PCA3 at different cutoffs. In consideration of the clinical need for a more specific biomarker for PCa, a cutoff of 30 was chosen for our study cohort. At the cutoff of 30, PCA3 score reached the best balance of sensitivity and specificity and considerably better performance than PSA. Further- Table 3. Diagnostic Performance Characteristics of PCA3 at Different Cutoffs Performance Urinary PCA3 Assay Characteristics (95% CI) Calculation Serum PSA at Cutoff of 4 ng/ml Cutoff of 25 Cutoff of 30 Cutoff of 35 Sensitivity % TP/(TP þ FN) 84.4 ( ) 77.9 ( ) 72.7 ( ) 64.9 ( ) Specificity % TN/(TN þ FP) 23.7 ( ) 58.8 ( ) 67.5 ( ) 71.6 ( ) PPV % TP/(TP þ FP) 30.5 ( ) 42.9 ( ) 47.1 ( ) 47.6 ( ) NPV % TN/(TN þ FN) 79.3 ( ) 87.0 ( ) 86.2 ( ) 83.7 ( ) LRþ Sensitivity/(1 specificity) 1.11 ( ) 1.89 ( ) 2.24 ( ) 2.29 ( ) LR (1 sensitivity)/specificity 0.66 ( ) 0.38 ( ) 0.40 ( ) 0.49 ( ) DOR LRþ/LR 1.68 ( ) 5.03 ( ) 5.55 ( ) 4.68 ( ) Youden index (Sensitivity þ specificity) Abbreviations: DOR, diagnostic odds ratio; FN, false negative; FP, false positive; LRþ, positive likelihood ratio; LR, negative likelihood ratio; NPV, negative predictive value; PCA3, prostate cancer antigen 3; PPV, positive predictive value; PSA, prostate-specific antigen; TN, true negative; TP, true positive. Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al 5
7 Figure 5. Probability of avoided biopsy (PAB) of prostate cancer antigen 3 (PCA3) in the whole study cohort and in the subgroup with prostatespecific antigen (PSA) level in the gray zone (4 10 ng/ml). Colors represent PCA3 cutoff scores of 25, 30, and 35. PAB is defined as the (number of false-positive PSA results number of false-positive PCA3 results)/number of false-positive PSA results. Figure 6. Receiver-operating characteristic curves for (A) the bivariable and (B) multivariable logistic regression models of combining prostate cancer antigen 3 (PCA3) score and prostate-specific antigen (PSA) level. more, use of PCA3 score at the cutoff of 30 could avoid 57.4% of unnecessary biopsies in the overall cohort and 70.3% in the subgroup with PSA level in the gray zone. These data suggest that the PCA3 assay can help reduce unnecessary biopsies triggered by elevated PSA. In a recent systematic review and meta-analysis of PCA3 utility in the diagnosis of PCa, 18 a total of 46 clinical trials comprising participants were analyzed. For the mixed biopsy studies, the pooled sensitivity, specificity, DOR, and AUC were 66%, 68%, 5.13, and 0.75, respectively. For the studies with a cutoff of 35, the pooled sensitivity, specificity, DOR, and AUC were 63%, 74%, 4.75, and 0.74, respectively. Compared with these data, our results are similar or better, further confirming that PCA3 is a reliable predictor of PCa. It has been reported that incorporating PCA3 score with other biomarkers or risk factors such as PSA level, age, race, family history, DRE findings, and previous biopsy can improve diagnostic accuracy. 23,24,29,30 In our bivariable logistic regression model combining PCA3 and PSA, the AUC was significantly higher than the AUC of PSA-only but not of PCA3-only. These data suggest that adding PCA3 to PSA can largely enhance the diagnostic value of PSA. Furthermore, the bivariable model was able to distinguish low-grade tumors (Gleason score ¼ 6) from high-grade tumors (Gleason score. 7), which may help reduce overdiagnosis and overtreatment via better risk stratification of the disease. No consensus has yet been reached on the relationship between PCA3 and tumor aggressiveness, some studies claiming a significant correlation of PCA3 score with Gleason score 16,31 35 and others finding no such correlation. 24,25,36 Although PCA3 score alone did not distinguish between low-grade and high-grade tumors in our study, the bivariable model combining PCA3 and PSA gained the ability to distinguish the 2 groups. In the multivariable model including PCA3, PSA, prostate volume, and repeated biopsy, the AUC was increased significantly over that of the bivariable model, which suggests that incorporating these 2 clinical characters can even further improve diagnostic accuracy. The major limitation of this study is the cohort size, especially the subgroup representing the population under- 6 Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al
8 going initial biopsy. Because of the small size of the initial biopsy group, a comparison between initial biopsy and repeated biopsy was not possible. However, the mixed biopsy population may better reflect the real patient population in clinical practice. Moreover, many observations on prostate volume and repeated biopsy were missing, which reduced the size of the cohort for multivariable logistic regression analysis. However, the usefulness of both the bivariable and multivariable models needs further internal and external validation before they can be used in the clinic. In summary, our results demonstrate that the urinary PCA3 assay is a sensitive and specific diagnostic tool for PCa in men at high risk of developing the disease. It overcomes the shortcomings of PSA, which may be elevated in noncancerous conditions such as enlarged prostate and inflammation. Combining PCA3 with PSA improves performance accuracy in identification of PCa with better stratification of cancer aggressiveness, which would provide better guidance for more effective biopsy decisions and lead to a considerable reduction of overdiagnosis and overtreatment of low-grade PCa. References 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer J Clin. 2016;66(1): Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2): Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4): Morote Robles J, Ruibal Morell A, Palou Redorta J, de Torres Mateos JA, Soler Rosello A. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol. 1988;14(5): Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update CA Cancer J Clin. 2010;60(2): Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5): Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis [discussion in Eur Urol. 2005; 48(3): ]. Eur Urol. 2005;48(3): Fowler FJ Jr, Barry MJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006;21(7): Pinkhasov GI, Lin YK, Palmerola R, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits: experience from 1000 consecutive cases. BJU Int. 2012;110(3): Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level, or ¼4.0 ng per milliliter. N Engl J Med. 2004;350(22): Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6): Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol. 2007;25(1): Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23): Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer [discussion in Eur Urol. 2003;44(1):15 16]. Eur Urol. 2003;44(1): de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62(9): Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res. 2015;34: Schmid M, Hansen J, Chun FK. Urinary prostate cancer antigen 3 as a tumour marker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867: Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016; 6: Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem. 2015;61(12): Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6(5): Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013;4(2): Auprich M, Augustin H, Budaus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int. 2012;109(11): Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32(36): Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179(4): Foj L, Mila M, Mengual L, et al. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clin Chim Acta. 2014; 435: de la Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185(6): Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013;19(9): Vlaeminck-Guillem V, Bandel M, Cottancin M, Rodriguez-Lafrasse C, Bohbot JM, Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score. Prostate. 2012;72(5): Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190(1): Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1): Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance [discussion in J Urol. 2008;179(5): ]. J Urol. 2008;179(5): Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59(1): Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70(1): van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012; 109(3): Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54(5): Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A. Urinary PCA3 score predicts prostate cancer multifocality. J Urol. 2011;185(4): Arch Pathol Lab Med PCA3 and Diagnosis of Prostate Cancer Cao et al 7
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationAVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY. The Progensa PCA3 test
AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that helps you and your doctor decide if a repeat biopsy
More informationClinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
european urology 54 (2008) 1081 1088 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for
More informationRational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care
Rational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care Rou Wang, MD 1 ; Arul M. Chinnaiyan, MD 1,2,3 ; Rodney L. Dunn, MS 1 ; Kirk J. Wojno, MD 2 ; and John T. Wei, MD, MS
More informationClinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions
Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions Alexandre de la Taille,*, Jacques Irani, Markus Graefen, Felix Chun, Theo de Reijke, Paul Kil, Paolo Gontero, Alain Mottaz and
More informationMAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test
MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that gives you the information you need to determine if
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationExternal Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome
EUROPEAN UROLOGY 58 (2010) 727 732 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer External Validation of Urinary PCA3-Based Nomograms to Individually Predict
More informationThe use of PCA3 in the diagnosis of prostate cancer
The use of PCA3 in the diagnosis of prostate cancer Daphne Hessels and Jack A. Schalken Abstract Although the routine use of serum PsA testing has undoubtedly increased prostate cancer detection, one of
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationAuthor: John V. Hegde, Darlene Veruttipong, Jonathan W. Said, Robert E. Reiter, Michael L. Steinberg, Christopher R. King, Amar U.
Accepted Manuscript Title: Prostate Cancer Antigen 3 (PCA3) Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-Free Survival in Clinically-Localized, Intermediate-
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationProstate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram
EUROPEAN UROLOGY 56 (2009) 659 668 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More information..biomarkers, running the gauntlet..
The long and winding round for the clinical introduction of a biomarker Molecular diagnostic of prostate cancer based on non invasive liquid biopsies..biomarkers, running the gauntlet.. Prof dr Jack A
More informationTumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer
Original papers Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer Tomaž Smrkolj 1, A F, Borut Gubina 1, B, E, F, Jure Bizjak 1, B, E, F, Kristina
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationDevelopment and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy
Development and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy Giovanni Lughezzani,*, Massimo Lazzeri, Alessandro Larcher, Giuliana Lista,
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2010 March 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2009 September 1; 115(17): 3879 3886. doi:10.1002/cncr.24447. Rational Approach to Implementation of PCA3 into Clinical Care
More informationAssessment of Long-Term Outcomes Associated With Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion at Repeat Biopsy
Assessment of Long-Term Outcomes Associated With Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion at Repeat Biopsy Selin Merdan, MEng 1 ; Scott A. Tomlins, MD, PhD 2,3 ; Christine L. Barnett,
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationResearch Article External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 643181, 6 pages doi:10.5402/2012/643181 Research Article External Validation of an Artificial Neural Network and Two Nomograms
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationProtein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Laboratory, Policy No. 69 Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer Next Review: October 2018 Last Review: December 2017 Effective: January
More informationProjecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer Jeanette K. Birnbaum 1, Ziding Feng 2,3,4, Roman Gulati 3, Jing Fan 4, Yair Lotan, 5 John T. Wei
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationDraft Comparative Effectiveness Review Number xx
Draft Comparative Effectiveness Review Number xx PCA3 Testing for the Diagnosis and Management of Prostate Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationCorrelation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden
Anatomic Pathology / Tissue and Urine T2:ERG Correlation Correlation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden Allison Young, MD, 1 Nallasivam Palanisamy, PhD, 1,2 Javed Siddiqui,
More informationThe role of PSA in detection and management of prostate cancer
The role of PSA in detection and management of prostate cancer Kirby R. The role of PSA in detection and management of prostate cancer. Practitioner 2016; 260(1792):17-21 Professor Roger Kirby MA MD FRCS
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationQuestions and Answers About the Prostate-Specific Antigen (PSA) Test
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More informationAssessment of performance and decision curve analysis
Assessment of performance and decision curve analysis Ewout Steyerberg, Andrew Vickers Dept of Public Health, Erasmus MC, Rotterdam, the Netherlands Dept of Epidemiology and Biostatistics, Memorial Sloan-Kettering
More informationA biopsy can be avoided in patients with positive DRE and negative MRI. Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.
A biopsy can be avoided in patients with positive DRE and negative MRI Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.C, Afula, Israel Financial and Other Disclosures Off-label use of drugs,
More informationDiagnostics guidance Published: 3 June 2015 nice.org.uk/guidance/dg17
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index Diagnostics guidance Published: 3 June 2015 nice.org.uk/guidance/dg17 NICE 2018. All rights reserved. Subject to Notice of rights
More informationIntermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA
Clinical Chemistry / PSA and Free PSA Method Differences Intermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA Patricia R. Slev, PhD, Sonia L. La ulu, and William L. Roberts,
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationActive Surveillance (AS) is an expectant management. Health Services Research
Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer Health Services Research Jianyu Liu, Paul R. Womble, Selin Merdan, David C. Miller, James E. Montie, Brian T. Denton on
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationThe Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study
Asian Journal of Andrology (2016) 18, 925 929 2016 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access ORIGINAL ARTICLE The Huashan risk calculators
More informationPredictive Performance Evaluation
Predictive Performance Evaluation Clinical Performance of the 4Kscore Test to Predict High-grade Prostate Cancer at Biopsy: A Meta-analysis of US and European Clinical Validation Study Results Stephen
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationProstate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients
ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2018 Origination: 7/2014 Next Review: 7/2019 Policy Blue Cross and Blue
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationThe Who s of Genomic Markers: Whom to Biopsy?
The Who s of Genomic Markers: Whom to Biopsy? 1.15.17 7:20-7:40 AM E. David Crawford, M.D. Professor of Surgery/Urology/ Radiation Oncology University of Colorado WSJ 5.10.16 2 Recent Advances in Prostate
More informationThe Role of PCP in Prostate Cancer Screening Beaver Creek Ma< T. Rosenberg
The Role of PCP in Prostate Cancer Screening Beaver Creek 2017 Ma< T. Rosenberg A Cri@cal Look at the Historical Flow Pa@ent concern Office visit History DRE PSA Biopsy Specimen with pathologist Too Many
More informationGenomic biomarkers in prostate cancer
Review Article Genomic biomarkers in prostate cancer Zachary Kornberg 1, Matthew R. Cooperberg 2, Daniel E. Spratt 3, Felix Y. Feng 1 1 Department of Radiation Oncology, 2 Department of Urology, UCSF Helen
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationProstate CancerTest TM. Test Report
Test Report Patient Information Requisition Number Patient Name ID Number Date of Birth Gender M Patient Phone Number Patient E-mail Name of Lab Lab Phone Number Name of Physician Date of Collection Date
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and the Prostate Health Index (PHI) This overview summarises the key issues for the Diagnostics
More information1. Introduction. Correspondence should be addressed to Zhongcheng Xin; and Liqun Zhou;
BioMed Research International Volume 2015, Article ID 596797, 7 pages http://dx.doi.org/10.1155/2015/596797 Clinical Study Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4 10 ng/ml
More informationOriginal Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men 50 years
Am J Clin Exp Urol 2014;2(4):332-336 www.ajceu.us /ISSN:2330-1910/AJCEU0002941 Original Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationComplexed Prostate-specific Antigen for the Detection of Prostate Cancer
Complexed Prostate-specific Antigen for the Detection of Prostate Cancer XAVIER FILELLA 1, DAVID TRUAN 2, JOAN ALCOVER 2, RAFAEL GUTIERREZ 2, RAFAEL MOLINA 1, FRANCISCA COCA 1 and ANTONIO M. BALLESTA 1
More informationSensitivity, specicity, ROC
Sensitivity, specicity, ROC Thomas Alexander Gerds Department of Biostatistics, University of Copenhagen 1 / 53 Epilog: disease prevalence The prevalence is the proportion of cases in the population today.
More informationRepeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly, D., Black, A., Murray, L., Nambirajan, T., Keane, P. F., & Gavin, A. (2009). Repeating an abnormal
More informationUsing Markov Models to Estimate the Impact of New Prostate Cancer Biomarkers
Using Markov Models to Estimate the Impact of New Prostate Cancer Biomarkers Brian Denton, PhD Associate Professor Department of Industrial and Operations Engineering February 23, 2016 Industrial and Operations
More informationSection Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
1 de 32 04-05-2013 19:24 Official reprint from UpToDate www.uptodate.com 2013 UpToDate Author Richard M Hoffman, MD, MPH Disclosures Section Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
More informationDipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer
Bladder Cancer 3 (2017) 45 49 DOI 10.3233/BLC-160068 IOS Press Research Report 45 Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer Richard S. Matulewicz a,b,, John Oliver DeLancey
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationResults. Conclusion. Keywords
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5a-reductase inhibitors Vincent Fradet, Paul Toren, Moliere Nguile-Makao,
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationLow serum neutrophil count predicts a positive prostate biopsy
Prostate Cancer and Prostatic Diseases (2012) 15, 386 -- 390 All rights reserved 1365-7852/12 www.nature.com/pcan ORIGINAL ARTICLE Low serum neutrophil count predicts a positive prostate biopsy K Fujita,
More informationDetermination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer
Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya
More informationRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
ORIGINAL ARTICLE (2011) 14, 53 57 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan Relationship between initial PSA density with future PSA kinetics and repeat biopsies
More informationPSA Isoforms in Prostate Cancer Detection
european urology supplements 5 (2006) 495 499 available at www.sciencedirect.com journal homepage: www.europeanurology.com PSA Isoforms in Prostate Cancer Detection Haluk Özen a, *, Sinan Sözen b a Department
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More information